Tailoring Treatment of EGFR-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care

Tailoring Treatment of EGFR-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care

Saturday, March 24, 2018 in Denver, CO
Breakfast -- Colorado Convention Center, 5:30 AM MT
Mile High Ballroom 2


5:30 AM - 6:00 AM: Breakfast and Registration

6:00 AM - 6:05 AM: Welcome and Introduction

6:05 AM - 6:25 AM: Overview of EGFR-Mutated NSCLC and Pharmacology of EGFR TKIs – Val R. Adams, PharmD, FCCP, BCOP

6:25 AM - 6:55 AM: Selecting First-line and Second-line Therapy in the Setting of EGFR-Mutated NSCLC – H. Jack West, MD

6:55 AM - 7:15 AM: Improving Patient Outcomes and Providing Cost-Effective Care in EGFR-Mutated NSCLC – Philip Schwieterman, PharmD, MHA

7:15 AM - 7:30 AM: Panel Discussion and Audience Question and Answer Session


Program Director
Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Philip Schwieterman, PharmD, MHA

Director of Oncology and Infusion Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington


Goal Statement
The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR-mutated non-small-cell lung cancer.

Target Audience
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care


Pharmacist Continuing Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-005-L01-P

Type of Activity

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.